Market position Fortrea is a global CRO with a strong oncology, anti-infectives/vaccines, and ophthalmology focus, presenting opportunities to cross-sell Fortrea's phase I-IV clinical trial management and post-approval services to Chiltern's hospital and healthcare network.

Growth potential Recent corporate moves include a Fortrea spinoff from Labcorp and revenue expansion with a 2026 outlook upgrade, signaling momentum and potential for integrated solutions that align with Chiltern’s expansion plans in diverse therapeutic areas.

Technology leverage Fortrea's technology suite and intelligent systems (FIT) plus existing tech stack (OneDrive, SuccessFactors, GitHub Copilot) offer a pathway for Chiltern to adopt scalable digital trial management, data capture, and analytics enhancements.

Strategic partnerships Fortrea's global footprint (90+ countries, 19k employees) and recent partnerships in gene therapy enable joint ventures or preferred provider arrangements that could extend Chiltern’s capabilities into advanced modalities and international sites.

Financial fit With annual revenue in the mid hundreds of millions and a clear growth trajectory, Fortrea presents a compelling candidate for service expansions, co-development agreements, or broader outsourcing of clinical operations to support Chiltern’s revenue growth and patient access solutions.